Section Arrow
Quote
VTGN.NASDAQ
- Vistagen Therapeutics, Inc.
(Financial Status)
Quotes are at least 15-min delayed:2026/11/06 18:05 EST
After Hours
Last
 0.1638
0 (0.00%)
Bid
0.1638
Ask
0.1802
High 0.1802 
Low 0.1638 
Volume 5.90K 
Regular Hours (Closed)
Last
 0.1638
-0.0014 (-0.85%)
Day High 
0.1769 
Prev. Close
0.1652 
1-M High
0.2696 
Volume 
520.18K 
Bid
0.1638
Ask
0.1802
Day Low
0.1638 
Open
0.1665 
1-M Low
0.1651 
Market Cap 
7.33M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.17 
20-SMA 0.19 
50-SMA 0.23 
52-W High 5.14 
52-W Low 0.1651 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.66/-0.81
Enterprise Value
7.58M
Balance Sheet
Book Value Per Share
0.55
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.11M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
KPTIKaryopharm Therapeutics Inc.0.0549-0.0052-8.65%-- 
After Hours 0.045898 -0.009002 -16.40%
INOInovio Pharmaceuticals1.215-0.235-16.21%-- 
After Hours 1.24 +0.025 +2.06%
LABTLakewood-Amedex Biotherapeutics Inc0.3863-0.1543-28.54%-- 
After Hours 0.399 +0.0127 +3.29%
CDTCdt Equity Inc1.31+0.464+54.85%0PE
After Hours 1.17 -0.14 -10.69%
MRNAModerna254.19+12.73+5.27%-- 
After Hours 256.01 +1.82 +0.72%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mentalfatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.